Audimooolam Vinod K, McPhail Mark J W, Sherwood Roy, Willars Chris, Bernal William, Wendon Julia A, Auzinger Georg
Crit Care. 2012 Nov 28;16(6):R228. doi: 10.1186/cc11883.
Acute liver failure (ALF) is a life-threatening multisystem illness complicated by multiple organ failure (MOF) and haemodynamic disturbances. Morbidity and mortality remains high and various prognostic and scoring models are in use to predict outcome. A recent observation in a large cohort of ALF patients suggested a prognostic value of troponin I (cTnI) and its role as a marker of subclinical myocardial injury and outcome.
Data from consecutive ALF patients over a four-year period from January 2007 to March 2011 were included. The aim of this study was to correlate any relationship that may exist between cTnI, mortality, severity of illness and non-hepatic organ failure.
A total of 218 subjects (age 36 (16 to 90) years, M:F 103:115) were studied, of which 136 had an elevated cTnI > 0.05 μg/L. Higher organ failure scores were found with positive cTnI: APACHE II (19.5 (3 to 51) vs 14 (2 to 51), P = 0.001), APACHE III (81 (15 to 148) vs 59 (8 to 172), P = < 0.001) SOFA (15 (4 to 20) vs 13 (2 to 21), P = 0.027) and SAPS (48 (12 to 96) vs 34 (12 to 97), P = 0.001). Patients with positive cTnI had higher serum creatinine (192 μmol/l (38 to 550) vs 117 μmol/l (46 to 929), P < 0.001), arterial lactate (0.25, P < 0.001) and a lower pH (-0.21, P = 0.002). Also a higher proportion required renal replacement therapy (78% vs 60%, P = 0.006). Patients with elevated cTnI more frequently required vasopressors-norepinephrine (73% vs 50%, P = 0.008). Elevated cTnI did not predict outcome as effectively as other models (AUROC 0.61 (95% CI 0.52 to 0.68)).
More than 60% of ALF patients in this study demonstrated elevated cTnI. Despite a close correlation with organ failure severity, cTnI was a poor independent predictor of outcome. cTnI may not represent true myocardial injury and may be better viewed as a marker of metabolic stress.
急性肝衰竭(ALF)是一种危及生命的多系统疾病,常并发多器官功能衰竭(MOF)和血流动力学紊乱。其发病率和死亡率仍然很高,目前使用各种预后和评分模型来预测结局。最近在一大群ALF患者中的观察表明,肌钙蛋白I(cTnI)具有预后价值,并且其作为亚临床心肌损伤和结局的标志物。
纳入2007年1月至2011年3月四年期间连续的ALF患者的数据。本研究的目的是关联cTnI、死亡率、疾病严重程度和非肝器官衰竭之间可能存在的任何关系。
共研究了218名受试者(年龄36(16至90)岁,男:女为103:115),其中136名患者的cTnI升高>0.05μg/L。cTnI阳性的患者器官衰竭评分更高:急性生理与慢性健康状况评分系统II(APACHE II)(19.5(3至51)对14(2至51),P = 0.001),APACHE III(81(15至148)对59(8至172),P =<0.001),序贯器官衰竭评估(SOFA)(15(4至20)对13(2至21),P = 0.027)和简化急性生理学评分(SAPS)(48(12至96)对34(12至97),P = 0.001)。cTnI阳性的患者血清肌酐更高(192μmol/l(38至550)对117μmol/l(46至929),P<0.001),动脉血乳酸更高(0.25,P<0.001),pH值更低(-0.21,P = 0.002)。此外,需要肾脏替代治疗的比例更高(78%对60%,P = 0.006)。cTnI升高的患者更频繁地需要血管加压药——去甲肾上腺素(73%对50%,P = 0.008)。与其他模型相比,cTnI对结局的预测效果不佳(受试者工作特征曲线下面积(AUROC)为0.61(95%置信区间0.52至0.68))。
本研究中超过60%的ALF患者cTnI升高。尽管与器官衰竭严重程度密切相关,但cTnI对结局的独立预测能力较差。cTnI可能并不代表真正的心肌损伤,或许更好地应将其视为代谢应激的标志物。